Daewoong Pharmaceutical Co., Ltd, founded in 1945 and headquartered in Seoul, South Korea, is a leading biopharmaceutical company committed to improving healthcare through innovative drug development and production. With a diverse portfolio, Daewoong specializes in prescription medicines, biologics, and over-the-counter products, focusing on areas such as gastroenterology, neurology, and diabetes care.
| Bond Name | Country | Maturity | Coupon(%) | |||
|---|---|---|---|---|---|---|
| No data found! | ||||||
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Daewoong Pharmaceutical began issuing corporate bonds in the late 1990s, with notable issuances including a ₩200 billion bond in 2020 to fund R&D initiatives. As of 2023, the company's bonds yield around 4.5%, slightly above the pharmaceutical industry average of 4.2%. Recent headlines highlighted their bond issuance to support the launch of a new biologic, showcasing a strategic approach to financing amidst increasing competition in the biopharmaceutical space.